Germany Archives

gals german life sciences startup accelerator sonormed tinnitracks ayoxxa personal medsystems pepperprint

News and Trends 15 Jan 2016

The German Accelerator in Boston’s 4 Rising Biotech Stars

During the 34th JP Morgan Healthcare Conference in San Francisco, the German Accelerator Life Sciences (GALS) announced the first four companies to participate in its Cambridge-based program. Germany has a long-standing reputation for life science innovation. However, most pharmaceutical and biotech companies are now headquartered in the US, and significantly more digital health solutions are […]

January 15, 2016 - 3 minutesmins - By Dani Bancroft

Universal cancer diagnostic test illumina bill gates grail guardant health ngs

News and Trends 11 Jan 2016

How about the $100M Holy ‘GRAIL’ in Cancer Diagnostics? A Universal Test Start-up Faces German Competition

Illumina, the €22Bn Market cap NGS specialist, and Bill Gates pooled a $100M to fund the startup, ‘Grail’, which will be used to find a universal cancer detection test for Doctors. The startup will be based in San Francisco (US) with additional financial backing to include Bill Gates amongst others. The tests in question are […]

January 11, 2016 - 3 minutesmins - By Dani Bancroft

biogen alzheimer proteros rodin therapeutics atlas neurology

News and Trends 8 Jan 2016

Epigenetics Baby of Proteros is Signing Up with Top US Neurology Specialists

Founded in just 2013 by German Proteros and the US Atlas Ventures, Rodin Therapeutics is working epigenetics into discovery of novel therapies for Neurological diseases. Now they have hooked one of the largest players in the field, Biogen, into a €446M partnership. Since its inception within Atlas Venture’s company-creating seed program in March 2013, Rodin […]

January 8, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 8 Jan 2016

Biotech of the week: Glycotope, the Biggest Biotech in Berlin

After the Christmas and New Year, we continue our journey across Europe to have a glimpse of it’s vast number of Biotechs. This week, we leave Finland behind and head South-West across the Baltic Sea and back to our home town, Berlin, to visit our biotech of the week, Glycotope. City: Berlin, Germany Founded: 2001 Employees: 200 (as of […]

January 8, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 8 Jan 2016

BioArt in Berlin: Making Dystopia Beautiful with Prostheses and the Transhuman Life

I met the curators of a BioArt Gallery in Berlin very recently and they invited me to their latest of exhibition ‘Prostheses: Transhuman Life’ by the Artist Susanna Hertrich. The exhibition, hosted by Christian De Lutz and Regine Rapp (the wonderfully warm curators of Art Laboratory Berlin) presented ‘wearable tech’ devices made to trigger emotions, […]

January 8, 2016 - 4 minutesmins - By Dani Bancroft

audi global bioenergies biofuels car isobutene

News and Trends 6 Jan 2016

Audi Strengthens Collaboration with French Biotech for the Future of Automotive Biofuels

Audi is entering a renewed collaboration agreement with French Global Bioenergies to further broaden the flexibility of their biofuels technology for Greener Cars. The Paris based Global Bioenergies approach to second-generation isobutene production (using non-edible sources of biomass – e.g. wood chips) has turned out to be hugely popular, earning a €1.4M investment back in […]

January 6, 2016 - 2 minutesmins - By Dani Bancroft

msd avelumab pdl1 immunooncology pfizer etinostat

News and Trends 5 Jan 2016

How these Latest Trials Prove PD-L1 as The Breakthrough Trend in Immuno-Oncology that is Here to Stay…

By targeting platinum resistant Ovarian cancer, Avelumab is a new anti-PD-L1 checkpoint inhibitor on the Cancer block. This just affirms how PD-L1 receptor is seen as the current breakthrough therapeutic target in Immuno-Oncology. Program-Death ligand 1 (PD-L1) is already a common target for mAbs in immuno-oncology. If expressed on the tumor cells, this enables the […]

January 5, 2016 - 3 minutesmins - By Dani Bancroft

crispr bayer therapeutics genetic disease joint venture london

News and Trends 22 Dec 2015

Serious Genetic Diseases have a New CRISPR Dream Duo Venture worth in Excess of €275M

Blood disorders, blindness and congenital heart disease? The new Bayer Life Science Center (BLSC) in Germany and CRISPR Therapeutics (Switzerland) have now created a joint Venture to tackle cures for these rare genetic defects. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise […]

December 22, 2015 - 2 minutesmins - By Dani Bancroft

berlin myelo therapeutics chemo cancer drug trial

News and Trends 15 Dec 2015

Berlin Biotech Breakthrough: Myelo is Only 3 Years old and Already Starting a Phase II Trial for Breast Cancer!

Myelo Therapeutics in Berlin (Germany) has been approved for a phase II trial for its Chemo-induced Neutropenia therapy for Breast cancer after completing a successful series B financing round. A reduced level of neutrophils (a type of leukocyte) is called neutropenia. It can leave a patient vulnerable to infection and to developing febrile neutropenia, a […]

December 15, 2015 - 3 minutesmins - By Dani Bancroft

probiodrug small molecule alzheimers disease trial

News and Trends 15 Dec 2015

Latest Small Molecule against Alzheimer’s Disease Success in Phase I Trials

Probiodrug‘s phase I tolerability and efficacy trial for Alzheimer’s didn’t quite go as planned, although results are in and it is still good news for this small molecule candidate. Probiodrug in Halle (Germany) is pioneering immunotherapy approaches to eliminate pyroglutamated (pGlu) Abeta, a highly toxic peptide that has been linked to the progression of Alzheimer’s […]

December 15, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 10 Dec 2015

“Structural Biology is changing the way we design drugs”

Structural biology, the study of the structure of biological macromolecules, is becoming a real asset in the drug development process. The PSDI meeting is THE not-to-be-missed event for the experts in this field. Labiotech.eu gives you a glimpse of the last trends discussed during this conference thanks to our exclusive interview with Dr Peter Reinemer, […]

December 10, 2015 - 5 minutesmins - By Joachim Eeckhout

News and Trends 8 Dec 2015

Merck Pulls out of Plans to Commercialize Cancer Drug After it Fails in Two Phase III Trials

Threshold Pharmaceuticals in the US has failed at getting its hypoxia prodrug evofosfamide through phase III trials for two types of cancer, and as a result has lost Merck’s partnership on the program. Evofosfamide (TH-302) is an investigational hypoxia-activated prodrug discovered by Threshold Pharmaceuticals in Pennsylvania (US). The prodrug is activated only at very low […]

December 8, 2015 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Germany

The German Accelerator in Boston’s 4 Rising Biotech Stars

How about the $100M Holy ‘GRAIL’ in Cancer Diagnostics? A Universal Test Start-up Faces German Competition

Epigenetics Baby of Proteros is Signing Up with Top US Neurology Specialists

Biotech of the week: Glycotope, the Biggest Biotech in Berlin

BioArt in Berlin: Making Dystopia Beautiful with Prostheses and the Transhuman Life

Audi Strengthens Collaboration with French Biotech for the Future of Automotive Biofuels

How these Latest Trials Prove PD-L1 as The Breakthrough Trend in Immuno-Oncology that is Here to Stay…

Serious Genetic Diseases have a New CRISPR Dream Duo Venture worth in Excess of €275M

Berlin Biotech Breakthrough: Myelo is Only 3 Years old and Already Starting a Phase II Trial for Breast Cancer!

Latest Small Molecule against Alzheimer’s Disease Success in Phase I Trials

“Structural Biology is changing the way we design drugs”

Merck Pulls out of Plans to Commercialize Cancer Drug After it Fails in Two Phase III Trials

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!